{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:40:23Z","timestamp":1780393223270,"version":"3.54.1"},"reference-count":56,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,3,1]]},"abstract":"<jats:p>High-capacity adenoviral (HC-Ad) vectors expressing B-domain\u2013deleted human or canine factor VIII from different liver-specific promoters were evaluated for gene therapy of hemophilia A. Intravenous administration of these vectors into hemophilic FVIII-deficient immunodeficient SCID mice (FVIIIKO-SCID) at a dose of 5\u2009\u00d7\u2009109 infectious units (IU) resulted in efficient hepatic gene delivery and long-term expression of supraphysiologic FVIII levels (exceeding 15\u2009000 mU\/mL), correcting the bleeding diathesis. Injection of only 5\u2009\u00d7\u2009107 IU still resulted in therapeutic FVIII levels. In immunocompetent hemophilic FVIII-deficient mice (FVIIIKO), FVIII expression levels peaked at 75\u2009000 mU\/mL but declined thereafter because of neutralizing anti-FVIII antibodies and a cellular immune response. Vector administration did not result in thrombocytopenia, anemia, or elevation of the proinflammatory cytokine interleukin-6 (IL-6) and caused no or only transient elevations in serum transaminases. Following transient in vivo depletion of macrophages before gene transfer, significantly higher and stable FVIII expression levels were observed. Injection of only 5\u2009\u00d7\u2009106 HC-Ad vectors after macrophage depletion resulted in long-term therapeutic FVIII levels in the FVIIIKO and FVIIIKO-SCID mice. Intravenous injection of an HC-Ad vector into a hemophilia A dog at a dose of 4.3\u2009\u00d7\u2009109 IU\/kg led to transient therapeutic canine FVIII levels that partially corrected whole-blood clotting time. Inhibitory antibodies to canine FVIII could not be detected, and there were no signs of hepatotoxicity or of hematologic abnormalities. These results contribute to a better understanding of the safety and efficacy of HC-Ad vectors and suggest that the therapeutic window of HC-Ad vectors could be improved by minimizing the interaction between HC-Ad vectors and the innate immune system.<\/jats:p>","DOI":"10.1182\/blood-2002-03-0823","type":"journal-article","created":{"date-parts":[[2003,2,12]],"date-time":"2003-02-12T19:59:36Z","timestamp":1045079976000},"page":"1734-1743","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":110,"title":["Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors"],"prefix":"10.1182","volume":"101","author":[{"given":"Marinee K. L.","family":"Chuah","sequence":"first","affiliation":[{"name":"From the Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium; Center for Molecular Medicine, University of Cologne, Germany; Department of Pathology, Queen's University, Kingston, ON, Canada; and Department of Cell Biology and Immunology, Vrije Universiteit, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Schiedner","sequence":"additional","affiliation":[{"name":"From the Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium; Center for Molecular Medicine, University of Cologne, Germany; Department of Pathology, Queen's University, Kingston, ON, Canada; and Department of Cell Biology and Immunology, Vrije Universiteit, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieven","family":"Thorrez","sequence":"additional","affiliation":[{"name":"From the Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium; Center for Molecular Medicine, University of Cologne, Germany; Department of Pathology, Queen's University, Kingston, ON, Canada; and Department of Cell Biology and Immunology, Vrije Universiteit, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Brown","sequence":"additional","affiliation":[{"name":"From the Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium; Center for Molecular Medicine, University of Cologne, Germany; Department of Pathology, Queen's University, Kingston, ON, Canada; and Department of Cell Biology and Immunology, Vrije Universiteit, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Johnston","sequence":"additional","affiliation":[{"name":"From the Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium; Center for Molecular Medicine, University of Cologne, Germany; Department of Pathology, Queen's University, Kingston, ON, Canada; and Department of Cell Biology and Immunology, Vrije Universiteit, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Gillijns","sequence":"additional","affiliation":[{"name":"From the Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium; Center for Molecular Medicine, University of Cologne, Germany; Department of Pathology, Queen's University, Kingston, ON, Canada; and Department of Cell Biology and Immunology, Vrije Universiteit, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Hertel","sequence":"additional","affiliation":[{"name":"From the Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium; Center for Molecular Medicine, University of Cologne, Germany; Department of Pathology, Queen's University, Kingston, ON, Canada; and Department of Cell Biology and Immunology, Vrije Universiteit, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Van Rooijen","sequence":"additional","affiliation":[{"name":"From the Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium; Center for Molecular Medicine, University of Cologne, Germany; Department of Pathology, Queen's University, Kingston, ON, Canada; and Department of Cell Biology and Immunology, Vrije Universiteit, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lillicrap","sequence":"additional","affiliation":[{"name":"From the Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium; Center for Molecular Medicine, University of Cologne, Germany; Department of Pathology, Queen's University, Kingston, ON, Canada; and Department of Cell Biology and Immunology, Vrije Universiteit, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De\u0301sire\u0301","family":"Collen","sequence":"additional","affiliation":[{"name":"From the Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium; Center for Molecular Medicine, University of Cologne, Germany; Department of Pathology, Queen's University, Kingston, ON, Canada; and Department of Cell Biology and Immunology, Vrije Universiteit, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"VandenDriessche","sequence":"additional","affiliation":[{"name":"From the Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium; Center for Molecular Medicine, University of Cologne, Germany; Department of Pathology, Queen's University, Kingston, ON, Canada; and Department of Cell Biology and Immunology, Vrije Universiteit, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kochanek","sequence":"additional","affiliation":[{"name":"From the Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Belgium; Center for Molecular Medicine, University of Cologne, Germany; Department of Pathology, Queen's University, Kingston, ON, Canada; and Department of Cell Biology and Immunology, Vrije Universiteit, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111901154480300_B1","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1089\/10430349950017095","article-title":"Advances toward gene therapy for hemophilia at the millennium.","volume":"10","author":"Kaufman","year":"1999","journal-title":"Hum Gene Ther."},{"key":"2019111901154480300_B2","doi-asserted-by":"crossref","first-page":"9973","DOI":"10.1073\/pnas.96.18.9973","article-title":"Gene therapy for the hemophilias [comment].","volume":"96","author":"Kay","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111901154480300_B3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1040-8428(98)00022-5","article-title":"Gene therapy for hemophilia: hopes and hurdles.","volume":"28","author":"Chuah","year":"1998","journal-title":"Crit Rev Oncol Hematol."},{"key":"2019111901154480300_B4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1521-2254(200101\/02)3:1<3::AID-JGM167>3.0.CO;2-H","article-title":"Gene therapy for hemophilia.","volume":"3","author":"Chuah","year":"2001","journal-title":"J Gene Med."},{"key":"2019111901154480300_B5","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1128\/JVI.70.10.7209-7212.1996","article-title":"Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs.","volume":"70","author":"Yang","year":"1996","journal-title":"J Virol."},{"key":"2019111901154480300_B6","first-page":"217","article-title":"Lack of persistence of E1-recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs.","volume":"3","author":"Fang","year":"1996","journal-title":"Gene Ther."},{"key":"2019111901154480300_B7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0298-180","article-title":"Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity [published erratum appears in Nat Genet. 1998;18:298].","volume":"18","author":"Schiedner","year":"1998","journal-title":"Nat Genet."},{"key":"2019111901154480300_B8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/1074-7613(94)90074-4","article-title":"MHC class Irestricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.","volume":"1","author":"Yang","year":"1994","journal-title":"Immunity."},{"key":"2019111901154480300_B9","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1128\/JVI.69.4.2004-2015.1995","article-title":"Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses.","volume":"69","author":"Yang","year":"1995","journal-title":"J Virol."},{"key":"2019111901154480300_B10","first-page":"137","article-title":"Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo.","volume":"3","author":"Yang","year":"1996","journal-title":"Gene Ther."},{"key":"2019111901154480300_B11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/hum.1995.6.2-185","article-title":"In vivo gene delivery and expression of physiological levels of functional human factor VIII in mice.","volume":"6","author":"Connelly","year":"1995","journal-title":"Hum Gene Ther."},{"key":"2019111901154480300_B12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1089\/hum.1996.7.2-183","article-title":"High-level tissue-specific expression of functional human factor VIII in mice.","volume":"7","author":"Connelly","year":"1996","journal-title":"Hum Gene Ther."},{"key":"2019111901154480300_B13","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1182\/blood.V88.10.3846.bloodjournal88103846","article-title":"Complete short-term correction of canine hemophilia A by in vivo gene therapy.","volume":"88","author":"Connelly","year":"1996","journal-title":"Blood."},{"key":"2019111901154480300_B14","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood.V91.9.3273","article-title":"Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy.","volume":"91","author":"Connelly","year":"1998","journal-title":"Blood."},{"key":"2019111901154480300_B15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood.V97.1.107","article-title":"Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs.","volume":"97","author":"Gallo-Penn","year":"2001","journal-title":"Blood."},{"key":"2019111901154480300_B16","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1089\/10430349950016807","article-title":"High-capacity adenoviral vectors for gene transfer and somatic gene therapy.","volume":"10","author":"Kochanek","year":"1999","journal-title":"Hum Gene Ther."},{"key":"2019111901154480300_B17","doi-asserted-by":"crossref","first-page":"13565","DOI":"10.1073\/pnas.93.24.13565","article-title":"A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal.","volume":"93","author":"Parks","year":"1996","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111901154480300_B18","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1089\/10430349950017473","article-title":"In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophiliac mice.","volume":"10","author":"Gallo-Penn","year":"1999","journal-title":"Hum Gene Ther."},{"key":"2019111901154480300_B19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2141.1993.tb08656.x","article-title":"Biological activity of recombinant factor VIII variants lacking the central B-domain and the heavy-chain sequence Lys713-Arg740: discordant in vitro and in vivo activity.","volume":"85","author":"Mertens","year":"1993","journal-title":"Br J Haematol."},{"key":"2019111901154480300_B20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1055\/s-0037-1614984","article-title":"The canine factor VIII cDNA and 5\u2032 flanking sequence.","volume":"79","author":"Cameron","year":"1998","journal-title":"Thromb Haemost."},{"key":"2019111901154480300_B21","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1126\/science.3264419","article-title":"Neonatal hepatitis induced by alpha 1-antitrypsin: a transgenic mouse model.","volume":"242","author":"Dycaico","year":"1988","journal-title":"Science."},{"key":"2019111901154480300_B22","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1089\/10430340252899000","article-title":"Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein a-I.","volume":"13","author":"Van Linthout","year":"2002","journal-title":"Hum Gene Ther."},{"key":"2019111901154480300_B23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/sj.gt.3301374","article-title":"Sustained expression of human apo A-I following adenoviral gene transfer in mice.","volume":"8","author":"De Geest","year":"2001","journal-title":"Gene Ther."},{"key":"2019111901154480300_B24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ng0595-119","article-title":"Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A [letter].","volume":"10","author":"Bi","year":"1995","journal-title":"Nat Genet."},{"key":"2019111901154480300_B25","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/301527a0","article-title":"A severe combined immunodeficiency mutation in the mouse.","volume":"301","author":"Bosma","year":"1983","journal-title":"Nature."},{"key":"2019111901154480300_B26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.V63.2.451.bloodjournal632451","article-title":"Development of factor VIII:C antibodies in dogs with hemophilia A (factor VIII:C deficiency).","volume":"63","author":"Giles","year":"1984","journal-title":"Blood."},{"key":"2019111901154480300_B27","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1089\/hum.1995.6.11-1363","article-title":"Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A.","volume":"6","author":"Chuah","year":"1995","journal-title":"Hum Gene Ther."},{"key":"2019111901154480300_B28","first-page":"612","article-title":"Proceedings: a more uniform measurement of factor VIII inhibitors.","volume":"34","author":"Kasper","year":"1975","journal-title":"Thromb Diath Haemorrh."},{"key":"2019111901154480300_B29","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.510230544","article-title":"Kupffer cell depletion by liposome-delivered drugs: comparative activity of intracellular clodronate, propamidine, and ethylenediaminetetraacetic acid.","volume":"23","author":"Van Rooijen","year":"1996","journal-title":"Hepatology."},{"key":"2019111901154480300_B30","doi-asserted-by":"crossref","first-page":"10379","DOI":"10.1073\/pnas.96.18.10379","article-title":"Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice [see comments].","volume":"96","author":"VandenDriessche","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111901154480300_B31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/hum.1998.9.3-353","article-title":"Bone marrow stromal cells as targets for gene therapy of hemophilia A.","volume":"9","author":"Chuah","year":"1998","journal-title":"Hum Gene Ther."},{"key":"2019111901154480300_B32","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1128\/JVI.71.4.3293-3298.1997","article-title":"A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging.","volume":"71","author":"Parks","year":"1997","journal-title":"J Virol."},{"key":"2019111901154480300_B33","doi-asserted-by":"crossref","first-page":"12816","DOI":"10.1073\/pnas.96.22.12816","article-title":"Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons.","volume":"96","author":"Morral","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111901154480300_B34","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1128\/JVI.76.4.1600-1609.2002","article-title":"Variables affecting in vivo performance of high-capacity adenovirus vectors.","volume":"76","author":"Schiedner","year":"2002","journal-title":"J Virol."},{"key":"2019111901154480300_B35","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1089\/10430349950017455","article-title":"Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors.","volume":"10","author":"Pastore","year":"1999","journal-title":"Hum Gene Ther."},{"key":"2019111901154480300_B36","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood.V94.12.3968","article-title":"Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity [see comments].","volume":"94","author":"Lozier","year":"1999","journal-title":"Blood."},{"key":"2019111901154480300_B37","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/(SICI)1521-2254(199909\/10)1:5<360::AID-JGM54>3.0.CO;2-Q","article-title":"Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits.","volume":"1","author":"Cichon","year":"1999","journal-title":"J Gene Med."},{"key":"2019111901154480300_B38","doi-asserted-by":"crossref","first-page":"8798","DOI":"10.1128\/JVI.71.11.8798-8807.1997","article-title":"The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors.","volume":"71","author":"Lieber","year":"1997","journal-title":"J Virol."},{"key":"2019111901154480300_B39","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood.V95.3.820.003k32_820_828","article-title":"Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector.","volume":"95","author":"Balague","year":"2000","journal-title":"Blood."},{"key":"2019111901154480300_B40","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood.V95.5.1594.005k34_1594_1599","article-title":"Sustained expression of human factor VIII in mice using a parvovirus-based vector.","volume":"95","author":"Chao","year":"2000","journal-title":"Blood."},{"key":"2019111901154480300_B41","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1182\/blood.V96.3.1173.015k34_1173_1176","article-title":"Therapeutic levels of human factor VIII and IX using HIV-1\u2013based lentiviral vectors in mouse liver.","volume":"96","author":"Park","year":"2000","journal-title":"Blood."},{"key":"2019111901154480300_B42","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1073\/pnas.95.10.5734","article-title":"Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A.","volume":"95","author":"Evans","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111901154480300_B43","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1089\/10430340050015626","article-title":"Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice.","volume":"11","author":"Chuah","year":"2000","journal-title":"Hum Gene Ther."},{"key":"2019111901154480300_B44","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V81.11.2925.2925","article-title":"Biochemical, immunological, and in vivo functional characterization of B-domain\u2013deleted factor VIII.","volume":"81","author":"Pittman","year":"1993","journal-title":"Blood."},{"key":"2019111901154480300_B45","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1055\/s-0037-1614449","article-title":"Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice.","volume":"81","author":"Connelly","year":"1999","journal-title":"Thromb Haemost."},{"key":"2019111901154480300_B46","doi-asserted-by":"crossref","first-page":"7866","DOI":"10.1073\/pnas.95.14.7866","article-title":"An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene.","volume":"95","author":"Morsy","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111901154480300_B47","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1006\/mthe.2001.0330","article-title":"Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors.","volume":"3","author":"Schnell","year":"2001","journal-title":"Mol Ther."},{"key":"2019111901154480300_B48","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1006\/mthe.2001.0329","article-title":"Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages.","volume":"3","author":"Zhang","year":"2001","journal-title":"Mol Ther."},{"key":"2019111901154480300_B49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/10430340152712719","article-title":"A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency.","volume":"13","author":"Raper","year":"2002","journal-title":"Hum Gene Ther."},{"key":"2019111901154480300_B50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/10430340152712665","article-title":"Toxicity of a first-generation adenoviral vector in rhesus macaques.","volume":"13","author":"Lozier","year":"2002","journal-title":"Hum Gene Ther."},{"key":"2019111901154480300_B51","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood.V82.8.2452.2452","article-title":"Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction.","volume":"82","author":"Gilles","year":"1993","journal-title":"Blood."},{"key":"2019111901154480300_B52","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1002\/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO;2-K","article-title":"Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis.","volume":"43","author":"Barrera","year":"2000","journal-title":"Arthritis Rheum."},{"key":"2019111901154480300_B53","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0167-7799(97)01019-6","article-title":"Transient suppression of macrophage functions by liposome-encapsulated drugs.","volume":"15","author":"van Rooijen","year":"1997","journal-title":"Trends Biotechnol."},{"key":"2019111901154480300_B54","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1089\/10430340252939041","article-title":"Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease.","volume":"13","author":"Ziegler","year":"2002","journal-title":"Hum Gene Ther."},{"key":"2019111901154480300_B55","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1089\/104303402320138934","article-title":"A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations.","volume":"13","author":"Kreppel","year":"2002","journal-title":"Hum Gene Ther."},{"key":"2019111901154480300_B56","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood.V99.11.3923","article-title":"A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo.","volume":"99","author":"Ehrhardt","year":"2002","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/5\/1734\/1262219\/h80503001734.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/5\/1734\/1262219\/h80503001734.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T00:15:59Z","timestamp":1583885759000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/5\/1734\/106645\/Therapeutic-factor-VIII-levels-and-negligible"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3,1]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,3,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-03-0823","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2003,3,1]]}}}